Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Lung Cancer. 2020 Sep 9;149:33–40. doi: 10.1016/j.lungcan.2020.08.023

Figure 2. Kaplan-Meier analyses of progression-free survival and overall survival.

Figure 2.

(A) Progression-free survival of patients in the ASA-OSI versus the OSI alone group, (B) Overall survival of patients in the ASA-OSI versus the OSI alone group. ASA-OSI: aspirin-osimertinib. OSI: osimertinib.